Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology's Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $3.3 million for Q1 2023.

• In Q1 2023, Non-Current Deferred Tax Liability fell 82.36% year-over-year to $3.3 million; the TTM figure through Mar 2023 stood at $3.3 million (down 82.36% YoY), while the FY2022 annual figure was $3.3 million, down 82.36% from the prior year.
• Non-Current Deferred Tax Liability came in at $3.3 million for Q1 2023 at Vir Biotechnology, roughly flat from $3.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $18.4 million in Q4 2021 to a low of $3.3 million in Q4 2020.
• A 5-year average of $7.3 million and a median of $3.3 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability soared 466.83% in 2021 and tumbled 82.36% in 2022, its largest moves.
• Vir Biotechnology's Non-Current Deferred Tax Liability stood at $3.3 million in 2019, then dropped by 1.57% to $3.3 million in 2020, then jumped by 466.83% to $18.4 million in 2021, then sank by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.3 million, $3.3 million, and $18.4 million for Q1 2023, Q4 2022, and Q3 2022 respectively.

Peer Comparison